Matt Zuga Sells 28,902 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Stock

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CFO Matt Zuga sold 28,902 shares of the company’s stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $1.72, for a total transaction of $49,711.44. Following the transaction, the chief financial officer now owns 231,744 shares of the company’s stock, valued at approximately $398,599.68. The trade was a 11.09 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Matt Zuga also recently made the following trade(s):

• On Tuesday, January 21st, Matt Zuga sold 4,364 shares of Acumen Pharmaceuticals stock. The stock was sold at an average price of $1.60, for a total transaction of $6,982.40.
• On Friday, January 3rd, Matt Zuga sold 13,235 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.84, for a total value of $24,352.40.

Acumen Pharmaceuticals Price Performance

ABOS stock opened at $1.65 on Friday. The firm has a 50 day moving average of $1.95 and a 200-day moving average of $2.46. The company has a market cap of $99.13 million, a price-to-earnings ratio of -1.20 and a beta of 0.02. Acumen Pharmaceuticals, Inc. has a 12-month low of $1.53 and a 12-month high of $5.09. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.14.

Acumen Pharmaceuticals (NASDAQ:ABOS) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.14). During the same period last year, the business earned ($0.24) earnings per share. As a group, equities analysts expect that Acumen Pharmaceuticals, Inc. will post -1.56 EPS for the current fiscal year.

Institutional Trading of Acumen Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. SG Americas Securities LLC purchased a new position in shares of Acumen Pharmaceuticals during the 3rd quarter worth approximately $44,000. American Century Companies Inc. grew its holdings in Acumen Pharmaceuticals by 31.3% during the 2nd quarter. American Century Companies Inc. now owns 45,444 shares of the company’s stock valued at $110,000 after buying an additional 10,840 shares during the last quarter. Rhumbline Advisers purchased a new position in Acumen Pharmaceuticals during the second quarter worth $127,000. Murchinson Ltd. purchased a new position in Acumen Pharmaceuticals in the 2nd quarter valued at about $136,000. Finally, Barclays PLC lifted its stake in shares of Acumen Pharmaceuticals by 189.1% during the third quarter. Barclays PLC now owns 61,997 shares of the company’s stock valued at $154,000 after buying an additional 40,551 shares during the period. Hedge funds and other institutional investors own 71.01% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Acumen Pharmaceuticals in a report on Wednesday, November 13th.

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.